P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA

Hemasphere · 2022 · PMC9430313

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Pharmacokinetic data showed a trend towards dose-proportional relationship and no evidence of accumulation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.